2026
conference-abstract
OpenAlex
Hexin Duan, Jia Chen, Jingbo Gong, Jie Li et autres
e18071 Background: The poor prognosis of high-risk locoregionally advanced nasopharyngeal carcinoma (LANPC) due to the high incidence of metastasis or local recurrence despite the development of radiotherapy. Immunotherapy has potential efficacy for LANPC, but the optimal treatment model remains unclear. This trial …
cn
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Quan Zuo, Jieqi Jia, Rong Liu, Jingsheng Zhao et autres
Objective To evaluate the efficacy and safety of S-1 maintenance chemotherapy after definitive chemoradiotherapy in patients with high-risk, locally advanced nasopharyngeal carcinoma (NPC). Methods A total of 536 patients with locally advanced NPC admitted to our hospital between August 2019 and November …
cn
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Wenxin Ding, Yechen Ma, Xu Tian, Hexin Duan et autres
• Neoadjuvant immuno-chemotherapy, followed by sequential radio-chemotherapy and immunotherapy maintenance improves prognosis of stage III NSCLC patients. • Neoadjuvant immuno-chemotherapy is an independent prognostic factors for stage III NSCLC patients. • Neoadjuvant immuno-chemotherapy results in an ORR of 65.45 % and a …
cn
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Lishui Niu, Honghua Wu, Ruihuan Gao, Liu Chen et autres
BACKGROUND: The third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) can penetrate blood-brain barrier and are effective for brain metastases (BMs). There is no consensus on the optimal sequence of local therapy (LT) and EGFR-TKIs for symptomatic BM patients because patients …
cn, us
(code pays fourni par la source)
Accès ouvert
2021
article
OpenAlex
Gang Xiao, Zhiyuan Liu, Xuan Gao, Han Wang et autres
Brain metastases (BM) is common in non-small-cell lung cancer (NSCLC) patients. Immune checkpoint inhibitors (ICIs) have gradually become a routine treatment for NSCLC BM patients. Currently, three PD-1 inhibitors (pembrolizumab, nivolumab and cemiplimab), one PD-L1 inhibitor (atezolizumab) and one CTLA-4 inhibitor (ipilimumab) …
cn
(code pays fourni par la source)
2013
conference-paper
OpenAlex
Jianzhuo Yan, Ying Wang, Liying Fang, Hexin Duan et autres
In order to enhance the service quality of network community, satisfy the growing demand of community users, this paper analyzes the content of network community from different aspects and provides a comprehensive method to divide the network community user group. On one …
cn
(code pays fourni par la source)
2013
conference-paper
OpenAlex
Jianzhuo Yan, Hexin Duan, Liying Fang, Ying Wang
Many people use the web as the main information source in their daily lives. However, most web pages contain non-information components, such as site bars, footers and ads, etc., which make it complicated to extract text from the original HTML documents. Because …
cn
(code pays fourni par la source)